Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Camp4 Therapeutics (CAMP) EBITDA (2023 - 2025)

Camp4 Therapeutics' EBITDA history spans 3 years, with the latest figure at -$40.3 million for Q4 2025.

  • For Q4 2025, EBITDA fell 203.37% year-over-year to -$40.3 million; the TTM value through Dec 2025 reached -$80.4 million, down 55.25%, while the annual FY2025 figure was -$80.4 million, 55.25% down from the prior year.
  • EBITDA for Q4 2025 was -$40.3 million at Camp4 Therapeutics, down from -$15.1 million in the prior quarter.
  • Across five years, EBITDA topped out at -$12.4 million in Q1 2025 and bottomed at -$40.3 million in Q4 2025.
  • The 3-year median for EBITDA is -$13.0 million (2023), against an average of -$16.1 million.
  • The largest YoY upside for EBITDA was 0.15% in 2025 against a maximum downside of 203.37% in 2025.
  • A 3-year view of EBITDA shows it stood at -$13.0 million in 2023, then decreased by 2.22% to -$13.3 million in 2024, then tumbled by 203.37% to -$40.3 million in 2025.
  • Per Business Quant, the three most recent readings for CAMP's EBITDA are -$40.3 million (Q4 2025), -$15.1 million (Q3 2025), and -$12.6 million (Q2 2025).